Goldman Sachs Keeps Their Buy Rating on Legend Biotech (LEGN)
In a report released today, from Goldman Sachs maintained a Buy rating on Legend Biotech, with a price target of $56.46.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Goldman Sachs, Legend Biotech also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued today. However, on the same day, TipRanks – Google reiterated a Hold rating on Legend Biotech (NASDAQ: LEGN).
Based on Legend Biotech’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $272.33 million and a GAAP net loss of $39.69 million. In comparison, last year the company earned a revenue of $160.21 million and had a GAAP net loss of $125.32 million
Read More on LEGN:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.